App-Quantinova.ai

Circulating tumor cells (CTCs) and epithelial mesenchymal transition (EMT) in primary breast cancer.

Marian Karaba - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A phase II clinical trial of neoadjuvant therapy with zoledronic acid for operable breast cancer.

Yoshie Nakayama - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Circulating tumor cells (CTC) as a biomarker of response in patients with extensive-stage small cell lung cancer (EX-SCLC).

Chao H. Huang - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

In vivo isolation of circulating tumor cells in prostate cancer patients by a medical device.

Gerit Theil - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

AP-19

Prevalence and quantity of circulating tumor cells (CTCs) after adjuvant chemotherapy in patients with HER2-negative early breast cancer (EBC).

Fabienne Schochter - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Detection of circulating tumor cells (CTCs) in stage T3-4 and/or N positive rectal cancer (RC) patients undergoing neoadjuvant therapy followed by curative surgery.

M. Giulia Zampino - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy.

Maria Spiliotaki - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A pilot feasibility study to evaluate the efficacy of lapatinib in eliminating HER2-positive tumor cells circulating in peripheral blood of women with metastatic breast cancer.

Sofia Agelaki - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Lapatinib

A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists- Group (BOOG) side study.

Wendy Onstenk - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Breast cancer

N/A

Utility of microsieve device for enumeration and miRNA expression profiling of CTCs for personalized cancer management.

Steven Tucker - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Clinical importance of circulating tumor cells in lung cancer patients.

Andrea Benedikova - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Impact of deviated balance of regulatory and cytotoxic T cells on release and reseeding of circulating tumor cells in hepatocellular carcinoma.

Xin-Rong Yang - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Nuclear localization of the androgen receptor in prostate cancer circulating tumor cells from men who have failed androgen deprivation therapy.

Joshua Michael Lang - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Prostate cancer

Androgen Tear

Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17.

Pedro Emanuel Rubini Liedke - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Letrozole

A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer.

Gini F. Fleming - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Temsirolimus

Immunocytochemistry staining for ER and PR in circulating tumor cells as compared to primary tumor or metastatic biopsy.

Farideh Z. Bischoff - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Use of the PRO Onc Assay (Prometheus) to measure HER2 overexpression/activation in circulating tumor cells (CTCs) in women with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute (SCRI) trial.

John D. Hainsworth - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival-

Markus Wallwiener - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: OS analysis.

Javier Salvador - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

N/A

Bevacizumab

Feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of breast cancer: An experience from India.

Mohan Kumar Somashekar - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Paclitaxel

Filters

1671 Abstracts